Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Raspollini, M. R.
Right arrow Articles by Taddei, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raspollini, M. R.
Right arrow Articles by Taddei, G. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:594-597, 2004
© 2004 European Society for Medical Oncology

Original Paper

c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study

Received 2 September 2003; revised 17 December 2003; accepted 22 December 2003

Background:

Recent studies have shown that several tumours express c-KIT, a growth factor receptor with tyrosine kinase activity; moreover, clinical results have shown the efficacy of the tyrosine kinase inhibitor, STI571, in c-KIT-positive tumours. The aim of this study was to determine the incidence and correlation with chemotherapy resistance of c-KIT expression in advanced serous, low grade of differentiation, ovarian carcinoma.

Patients and methods:

We performed an immunohistochemistry analysis of 56 patients with advanced serous ovarian carcinomas using archival paraffin-embedded specimens.

Results:

Intense c-KIT immunostaining was observed in 51.7% of cases. c-KIT expression was statistically correlated with progression of disease after first-line chemotherapy (P = 0.029).

Conclusions:

c-KIT is also expressed in ovarian carcinoma and it is statistically correlated with chemotherapy resistance. This study suggests the necessity for clinical trials confirming the utility of the tyrosine kinase inhibitor, STI571, in ovarian advanced cancer patients with c-KIT overexpression when these patients have shown no clinical response to conventional chemotherapy.

M. R. Raspollini1,*, G. Amunni2, A. Villanucci2, G. Baroni1, A. Taddei3 and G. L. Taddei1

1 Department of Human Pathology and Oncology, 2 Department of Gynecology, Perinatology and Reproductive Medicine, 3 Department of Surgery, University of Florence, Florence, Italy

Key words: chemotherapy, c-KIT, ovarian carcinoma, prognosis, STI571


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Zhang, C. Balch, M. W. Chan, H.-C. Lai, D. Matei, J. M. Schilder, P. S. Yan, T. H-M. Huang, and K. P. Nephew
Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Cancer Res., June 1, 2008; 68(11): 4311 - 4320.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
K. M. Sheehan, V. S. Calvert, E. W. Kay, Y. Lu, D. Fishman, V. Espina, J. Aquino, R. Speer, R. Araujo, G. B. Mills, et al.
Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma
Mol. Cell. Proteomics, April 1, 2005; 4(4): 346 - 355.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.